New probiotic therapy using L-DOPA for Parkinson's disease
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease
This study is exploring a new way to help people with Parkinson's disease by using specially designed probiotics that can deliver a steady supply of L-DOPA to the brain, which may help reduce movement problems and improve daily life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10688149 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating Parkinson's disease by using genetically engineered probiotic bacteria that produce L-DOPA, a key neurotransmitter. The goal is to provide a continuous and stable delivery of L-DOPA to the brain, which could help alleviate the motor symptoms associated with the disease. By avoiding the traditional oral dosing method, which can lead to fluctuations in medication levels and side effects, this therapy aims to improve the quality of life for patients. The study will involve the development and testing of these probiotics to ensure they effectively deliver L-DOPA without causing dyskinesia or other complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are currently experiencing motor symptoms and are seeking improved treatment options.
Not a fit: Patients who are not diagnosed with Parkinson's disease or those who are in advanced stages of the disease with severe complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for Parkinson's disease, reducing motor complications and improving patient quality of life.
How similar studies have performed: While the use of probiotics in therapy is a growing field, this specific approach of using genetically engineered probiotics for L-DOPA delivery is novel and has not been extensively tested in previous studies.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Kanthasamy, Anumantha Gounder — University of Georgia
- Study coordinator: Kanthasamy, Anumantha Gounder
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.